.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,244,450

« Back to Dashboard

Details for Patent: 7,244,450

Title:Compositions and methods for treating lymphoma
Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
Inventor(s): Sarris; Andreas H. (Houston, TX), Cabanillas; Fernando (Houston, TX), Logan; Patricia M. (Vancouver, CA), Burge; Clive T. R. (Brentwood Bay, CA), Goldie; James H. (Vancouver, CA), Webb; Murray S. (Delta, CA)
Assignee: Inex Pharmaceuticals Corporation (CA) Board of Regents, The University of Texas System (Austin, TX)
Filing Date:Dec 04, 2003
Application Number:10/728,738
Claims:1. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with Rituximab, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.

2. The method of claim 1, wherein said liposome comprises sphingomyelin and cholesterol.

3. The method of claim 2, wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol % sphingomyelin/mol % cholesterol) and 50/50 (mol % sphingomyelin/mol % cholesterol).

4. The method of claim 3, wherein the ratio of sphingomyelin to cholesterol is 55/45 (mol % sphingomyelin/mol % cholesterol).

5. The method of claim 1, wherein said vincristine is administered at a dosage of between 1.4 2.4 mg/m.sup.2.

6. The method of claim 1, wherein said lymphoma is non-Hodgkin's lymphoma.

7. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with iodine 131 (131I) Lym-1, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.

8. The method of claim 7, wherein said liposome comprises sphingomyelin and cholesterol.

9. The method of claim 8, wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol % sphingomyelin/mol % cholesterol) and 50/50 (mol % sphingomyelin/mol % cholesterol).

10. The method of claim 7, wherein said lymphoma is non-Hodgkin's lymphoma.

11. A method of treating a relapsed cancer in a human, said method comprising coadministering to said human a pharmaceutical composition comprising liposome-encapsulated vincristine with iodine 131 (131I) tositumomab, wherein said relapsed cancer is a lymphoma or leukemia, and wherein said human has previously undergone at least one multi-agent combination regime.

12. The method of claim 11, wherein said liposome comprises sphingomyelin and cholesterol.

13. The method of claim 12, wherein the ratio of sphingomyelin to cholesterol is between 75/25 (mol % sphingomyelin/mol % cholesterol) and 50/50 (mol % sphingomyelin/mol % cholesterol).

14. The method of claim 11, wherein said lymphoma is non-Hodgkin's lymphoma.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc